Dr. Gupta is a national leader in the field of structural heart disease. As a pioneer in the field of interventional cardiology, he was an early leader in transcatheter aortic valve replacement (TAVR) and leads several groundbreaking studies, including seeking new indications for TAVR.
Currently, Dr. Gupta also serves as the clinical co-director for the division of cardiovascular medicine at the University of Maryland School of Medicine. He is focused on developing a division that trains cardiologists dedicated to clinical care, education and research.
A focus of his research includes evaluating new therapies for the treatment of cardiovascular disease. He was the site principal investigator for the PARTNER 2 trial, Galileo Trial, Early TAVR Trial and the Medtronic Low-Risk randomized trial for TAVR.
Dr. Gupta is the principal investigator of the ALIGN-AR Trial assessing TAVR in patients with severe aortic regurgitation. In addition, he is involved in renal denervation studies, including the SYMPLICITY-HTN3 trial and Reduce HTN: Reinforce trial. He is the site principal investigator for the OCEAN (a) Trial, assessing a siRNA to reduce the pro-atherosclerotic Lipoprotein(a).
